...Davien Deraedt; Saartje Verfaillie; Jokke Wynants; Kristof Cuppens Introduction: Treatment with topotecan is standard-of-care therapy for relapsed small-cell lung cancer (SCLC). Both oral and intravenous administrations of topotecan have been extensively researched and are found to be equally...

...Keita Kawakado; Shunsuke Ito; Kento Kono; Yuki Mitarai; Takashi Yanagawa; Makoto Nagasaki Introduction: Combination therapy of atezolizumab and chemotherapy has become the standard treatment for small-cell lung cancer. Immune-related adverse events (irAEs) can occur during immune checkpoint...

...Sarah Maryon Hayes; Christine Wiese; Robert Schneidewend Tumor lysis syndrome (TLS) is an oncologic emergency most frequently associated with initial treatment of hematologic malignancies and high-tumor burden solid tumors such as small-cell lung cancer (SCLC). Most often, TLS is associated...

...Yuka Aida; Kensuke Nakazawa; Toshihiro Shiozawa; Ryoko Ogawa; Takumi Kiwamoto; Yuko Morishima; Toru Sakamoto; Ikuo Sekine; Nobuyuki Hizawa Small-cell lung cancer (SCLC) is highly sensitive to platinum-based chemotherapy. However, its indication in patients with a poor performance status (PS...

...Toshihiro Shiozawa; Ikuo Sekine; Yuka Aida; Hiroko Watanabe; Kensuke Nakazawa; Koichi Kurishima; Hiroaki Satoh; Nobuyuki Hizawa Background: Sensitive-relapsed small-cell lung cancer (SCLC) is thought to be sensitive to chemotherapy; therefore, second-line chemotherapy is recommended. Although...

... recommendations for this group rely on data from the similar but more common small-cell carcinoma of the lungs. Immune checkpoint inhibitors are being investigated for the treatment of metastatic small-cell lung cancer with positive outcome. We applied the experience from these studies to a case of metastatic...

... swelling, neck distension, and enlarged veins of the upper chest, which developed over a period of 5 weeks in a 46-year-old patient on a clinical trial with small-cell lung cancer, is reported. Computed tomography scan of the chest revealed slight enlargement of a superior conglomerate mediastinal...

.... Characterization of these tumors is best accomplished with tissue biopsy, as peripheral tumor markers commonly used in NECs are of little utility. Therapeutic strategies often involve chemotherapeutic regimens that have been used to treat small-cell lung cancer. Recent studies have shown that programmed death...

... investigation in advanced non-small cell lung cancer, small-cell lung cancer and high-grade neuroendocrine tumors in a Phase II clinical trial entitled TRIPLE THREAT (NCT02489903), which reexposes patients to previously effective but refractory platinum doublets after treatment with RRx-001. The purpose...

...Yoshitaka Yagi; Young Hak Kim; Noriyuki Tajima; Kiichiro Baba; Kensaku Aihara; Hong Hyun Soo; Shinpachi Yamaoka; Michiaki Mishima Lung cancer is the leading cause of cancer-related death worldwide. Small-cell lung cancer (SCLC) accounts for approximately 15% of all lung cancers. It is characterized...

... surgery. He was treated with three chemotherapy regimens used for the management of small-cell lung cancer with extensive disease. However, none of them could be maintained because of tumor progression. He was then treated with bevacizumab plus modified FOLFOX6 as the fourth-line regimen. Dramatic tumor...